Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.

Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG.

Br J Cancer. 2008 May 6;98(9):1525-32. doi: 10.1038/sj.bjc.6604318. Epub 2008 Apr 29.

2.

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.

Schmidt M, Bremer E, Hasenclever D, Victor A, Gehrmann M, Steiner E, Schiffer IB, Gebhardt S, Lehr HA, Mahlke M, Hermes M, Mustea A, Tanner B, Koelbl H, Pilch H, Hengstler JG.

Br J Cancer. 2007 Jan 29;96(2):241-7. Epub 2007 Jan 9.

3.

Oncogene-blocking therapies: new insights from conditional mouse tumor models.

Hengstler JG, Bockamp EO, Hermes M, Brulport M, Bauer A, Schormann W, Schiffer IB, Hausherr C, Eshkind L, Antunes C, Franzen A, Krishnamurthi K, Lausch E, Lessig R, Chakrabarti T, Prawitt D, Zabel B, Spangenberg C.

Curr Cancer Drug Targets. 2006 Nov;6(7):603-12. Review.

PMID:
17100566
4.

ErbB-3 predicts survival in ovarian cancer.

Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.

J Clin Oncol. 2006 Sep 10;24(26):4317-23. Epub 2006 Aug 8.

PMID:
16896008
5.

ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.

Spangenberg C, Lausch EU, Trost TM, Prawitt D, May A, Keppler R, Fees SA, Reutzel D, Bell C, Schmitt S, Schiffer IB, Weber A, Brenner W, Hermes M, Sahin U, Türeci O, Koelbl H, Hengstler JG, Zabel BU.

Cancer Res. 2006 Apr 1;66(7):3715-25.

6.

Dephosphorylation of p-ERK1/2 in relation to tumor remission after HER-2 and Raf1 blocking therapy in a conditional mouse tumor model.

Hausherr CK, Schiffer IB, Gebhard S, Banić A, Tanner B, Kolbl H, Thoenes E, Beckers T, Spangenberg C, Prawitt D, Trost T, Zabel B, Oesch F, Hermes M, Hengstler JG.

Mol Carcinog. 2006 May;45(5):302-8.

PMID:
16496387
7.

Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.

Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, Heimerdinger CK, Hengstler JG, Fritz G, Bockamp EO, Prawitt D, Zabel BU, Spangenberg C.

Cancer Res. 2005 Feb 1;65(3):840-9.

8.

4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models.

Eger K, Hermes M, Uhlemann K, Rodewald S, Ortwein J, Brulport M, Bauer AW, Schormann W, Lupatsch F, Schiffer IB, Heimerdinger CK, Gebhard S, Spangenberg C, Prawitt D, Trost T, Zabel B, Sauer C, Tanner B, Kolbl H, Krugel U, Franke H, Illes P, Madaj-Sterba P, Bockamp EO, Beckers T, Hengstler JG.

Biochem Biophys Res Commun. 2004 Oct 22;323(3):979-86.

PMID:
15381096
9.

Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.

Schiffer IB, Gebhard S, Heimerdinger CK, Heling A, Hast J, Wollscheid U, Seliger B, Tanner B, Gilbert S, Beckers T, Baasner S, Brenner W, Spangenberg C, Prawitt D, Trost T, Schreiber WG, Zabel B, Thelen M, Lehr HA, Oesch F, Hengstler JG.

Cancer Res. 2003 Nov 1;63(21):7221-31.

10.

No influence of magnetic fields on cell cycle progression using conditions relevant for patients during MRI.

Schiffer IB, Schreiber WG, Graf R, Schreiber EM, Jung D, Rose DM, Hehn M, Gebhard S, Sagemüller J, Spiess HW, Oesch F, Thelen M, Hengstler JG.

Bioelectromagnetics. 2003 May;24(4):241-50.

PMID:
12696084
11.

Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice.

Hast J, Schiffer IB, Neugebauer B, Teichman E, Schreiber W, Brieger J, Kim DW, Gebhard S, Born CJ, Strugala M, Sagemüller J, Brenner W, Mann WJ, Oesch F, Thelen M, Hengstler JG.

Anticancer Res. 2002 Mar-Apr;22(2A):677-88.

PMID:
12014637

Supplemental Content

Loading ...
Support Center